GC Biopharma Corp. Q3 operating profit KRW 49.2 billion on revenue of KRW 522.1 billion (consolidated)
AI summary · Not investment advice
In Q3, the company sold KRW 522.1 billion worth and earned KRW 49.2 billion from its main business, up 68.5% from a year earlier and up 2746.1% from the previous quarter.
Operating profit · 3 months
KRW 49.2 billion
Key facts
- Revenue (3 months)
- KRW 522.1 billion
- Net income (3 months)
- KRW 208.5 billion
- Period
- Q3 (cumulative Jan 1, 2026 to Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 609.5 billion
- Revenue (year to date)
- KRW 1.4 trillion
- Operating profit (prior-year 3 months)
- KRW 29.2 billion
- Operating profit (year to date)
- KRW 62.7 billion
- Net income (prior-year 3 months)
- KRW 18.1 billion
- Net income (year to date)
- KRW 229.7 billion
Commentary
AI commentary · Not investment advice
What happened
GC Biopharma (Green Cross) reported its consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 522.1 billion. That is 14.3% lower than the same 3 months a year earlier and 24.0% higher than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW 49.2 billion. That is 68.5% higher than a year earlier and 2746.1% higher than the previous quarter.
What changes for shareholders
Net income (the final profit after taxes and all other costs) for the 3 months was KRW 208.5 billion. That is 1048.9% higher than a year earlier and 19754.9% higher than the previous quarter.
For the year so far, sales are KRW 1,378.9 billion. Operating profit is KRW 62.7 billion. Net income is KRW 229.7 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
G